Weissmann Joerg, Mueller Angelika, Messinger Diethelm, Parkin Christopher G, Amann-Zalan Ildiko
Roche Diagnostics Deutschland GmbH, Mannheim, Germany.
Biometrics Department, IST GmbH, Mannheim, Germany.
J Diabetes Sci Technol. 2015 Jul 29;10(1):76-84. doi: 10.1177/1932296815595984.
This study aimed to evaluate the effects of information management system (IMS) use with individuals with type 1 and type 2 diabetes who were treated in outpatient settings.
In this 7-month, prospective, observational study, 965 adults with diabetes, mean (SD) baseline HbA1c 8.61(1.2)% (70.6[13.1] mmol/mol), were recruited from 132 outpatient care centers in Germany and Denmark. HbA1c was measured at baseline, month 4, and month 7. IMS reports were generated from uploaded self-monitored blood glucose data and therapy adjustments were documented at months 1 and 4. Hypoglycemic events were documented.
Mean (SD) HbA1c decreased from baseline in type 1 and type 2 diabetes patients at month 4 (-0.61[1.03]% (-6.7[11.3] mmol/mol), n = 213; -0.88[1.22]% (-9.6[13.3] mmol/mol), n = 589, respectively) and month 7 (-0.64[1.02]% (-7.0[11.1] mmol/mol), n = 219; -0.93[1.27]% (-10.2[13.9] mmol/mol), n = 594, respectively), all P < .0001, with no increase in hypoglycemic events. Therapy was adjusted in 106(42.7)% type 1 and 349(52.4)% type 2 diabetes patients at months 1 and 105(42.3)% type 1 and 282(42.3)% type 2 diabetes patients at month 4. Physicians used IMS reports to make therapy adjustments in 90% of patients at month 1 and 86% of patients at month 4.
Integration of the IMS into outpatient care facilitates significant improvements in glycemic control.
本研究旨在评估信息管理系统（IMS）在1型和2型糖尿病门诊患者中的应用效果。
在这项为期7个月的前瞻性观察性研究中，从德国和丹麦的132个门诊护理中心招募了965名成年糖尿病患者，其平均（标准差）基线糖化血红蛋白（HbA1c）为8.61（1.2）%（70.6[13.1] mmol/mol）。在基线、第4个月和第7个月测量HbA1c。根据上传的自我监测血糖数据生成IMS报告，并在第1个月和第4个月记录治疗调整情况。记录低血糖事件。
1型和2型糖尿病患者的平均（标准差）HbA1c在第4个月时从基线水平下降（分别为-0.61[1.03]%（-6.7[11.3] mmol/mol），n = 213；-0.88[1.22]%（-9.6[13.3] mmol/mol），n = 589），在第7个月时也下降（分别为-0.64[1.02]%（-7.0[11.1] mmol/mol），n = 219；-0.93[1.27]%（-10.2[13.9] mmol/mol），n = 594），所有P <.0001，且低血糖事件没有增加。在第1个月，106名（42.7%）1型糖尿病患者和349名（52.4%）2型糖尿病患者的治疗进行了调整；在第4个月，105名（42.3%）1型糖尿病患者和282名（42.3%）2型糖尿病患者的治疗进行了调整。在第1个月，90%的患者医生使用IMS报告进行治疗调整；在第4个月，86%的患者医生使用IMS报告进行治疗调整。
将IMS整合到门诊护理中有助于显著改善血糖控制。
